Verified Sponsor Execution & Regulatory Ledger
| Sponsor Metric | Verified Count / Rate |
|---|---|
| Phase II & III Protocols (2018 to 2026) | 27 |
| Active Pipeline (Recruiting Now) | 13 (8) |
| Completed vs Stopped Early | 12 / 0 (0.0%) |
| Median Closed Actual Enrollment | 233 participants |
| Physical Hospital Site Disclosure | 100.0% named hospitals |
| FDA Drugs@FDA Original NDA/BLA Approvals | 0 (0 since 2018) |
Top Partner U.S. Hospital Clinical Research Sites
| Hospital Research Site | Location | Shared Protocols |
|---|---|---|
| Beijing Hospital | Beijing, Beijing Municipality | 4 |
Indexed Multi-Center Phase II & III Protocols
| NCT Identifier | Protocol Brief Title | Phase | Status |
|---|---|---|---|
| NCT07687186 | Qishen Yiqi Dripping Pills in Treatment of Chronic Heart FailUre | Phase III | RECRUITING |
| NCT06685978 | Efficacy and Safety of Xiangjurupining Capsule for Hyperplasia of Mammary Glands | Phase III | RECRUITING |
| NCT04983043 | Efficacy and Safety of QiShen YiQi Dripping Pills in Chronic Heart Failure | Phase II | COMPLETED |
| NCT04944706 | Efficacy and Safety of Qishenyiqi Dripping Pills for Treating Chronic Heart Failure With Preserved Ejection Fraction | Phase II | COMPLETED |
| NCT06068465 | A Study of the Safety and Efficacy of Pimavanserin in Patients With Parkinson's Disease Psychosis | Phase III | COMPLETED |
Explore interactive annual charts and M&A subsidiary rollups in the Tasly Pharmaceutical Group Co Interactive Dossier, benchmark peers in Rare Genetic, Women's Health, and Other, or review the Healthcare Price & Patent Cliff Crosswalk.